Benitec Biopharma (BNTC) to Release Earnings on Monday

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.19. On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Benitec Biopharma Trading Up 4.4 %

BNTC stock opened at $15.05 on Monday. The firm has a 50-day moving average of $13.41 and a two-hundred day moving average of $11.84. Benitec Biopharma has a 12 month low of $5.74 and a 12 month high of $16.90. The company has a market cap of $352.94 million, a price-to-earnings ratio of -9.97 and a beta of 0.34.

Insider Buying and Selling

In related news, Director Suvretta Capital Management, L purchased 900,000 shares of the company's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the completion of the transaction, the director now directly owns 8,793,245 shares in the company, valued at approximately $114,312,185. The trade was a 11.40 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 1.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $28.00 price target on shares of Benitec Biopharma in a report on Monday, March 24th. JMP Securities raised their target price on Benitec Biopharma from $18.00 to $20.00 and gave the stock a "market outperform" rating in a research note on Thursday, April 10th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $24.71.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.